Vaccine-specific immune responses against *Mycobacterium ulcerans* infection in a low-dose murine challenge model.

Kirstie M. Mangas¹, Andrew H. Buultjens¹, Jessica L. Porter¹, Sarah L. Baines¹, Estelle Marion², Laurent Marsollier², Nicholas J. Tobias^{3,4}, Sacha J. Pidot¹, Kylie M. Quinn⁵, David J. Price^{6,7}, Katherine Kedzierska¹, Weiguang Zeng¹, David C. Jackson¹, Brendon Y. Chua^{1,*} and Timothy P. Stinear^{1,*}.

1. Department of Microbiology and Immunology, Doherty Institute, University of Melbourne

2. CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France

3. Molekulare Biotechnologie, Fachbereich Biowissenschaften, Goethe-Universität Frankfurt, Frankfurt am Main, Germany

4. LOEWE Centre for Translational Biodiversity in Genomics (TBG), Germany

5. Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia.

6. Victorian Infectious Diseases Reference Laboratory Epidemiology Unit at The Peter Doherty Institute for Infection & Immunity, The University of Melbourne and Royal Melbourne Hospital, VIC 3000, Australia

7. Centre for Epidemiology & Biostatistics, Melbourne School of Population & Global Health, The University of Melbourne, VIC 3010, Australia

* Joint senior authors

Running title: Immune responses against Buruli ulcer

Abstract:

The neglected tropical disease Buruli ulcer (BU) is an infection of subcutaneous tissue with *Mycobacterium ulcerans*. There is no effective BU vaccine. Here, we assessed an experimental prime-boost vaccine in a low-dose murine tail infection model. We used the enoyl-reductase (ER) domain of the *M. ulcerans* mycolactone polyketide synthases electrostatically coupled with a previously described TLR-2 agonist-based lipopeptide adjuvant, R₄Pam2Cys. Mice were vaccinated and then challenged via tail inoculation with 14-20 colony forming units (CFU) of an engineered bioluminescent strain of *M. ulcerans*. Mice receiving either the experimental ER vaccine or *Mycobacterium bovis* Bacille Calmette-Guérin (BCG) were equally well protected, with both groups faring significantly better than non-vaccinated animals ($p<0.05$). A suite of 29 immune parameters were assessed in the mice at the end of the experimental period. Multivariate statistical approaches were then used to interrogate the immune response data to develop disease-prognostic models. High levels of IL-2 and low IFN- γ produced in the spleen best predicted control of infection across all vaccine groups. Univariate logistic regression then revealed vaccine-specific profiles of protection. High titres of ER-specific IgG serum antibodies together with IL-2 and IL-4 in the draining lymph node (DLN) were associated with protection induced by the experimental ER vaccine. In contrast, high titres of IL-6, TNF- α , IFN- γ and IL-10 in the DLN and low IFN γ titres in the spleen were associated with protection following BCG vaccination. This study suggests an effective BU vaccine must induce localized, tissue-specific immune profiles with controlled inflammatory responses at the site of infection.

48 Introduction:

49 Buruli ulcer (BU) is a disease primarily of the subcutaneous tissue caused by infection with
 50 *Mycobacterium ulcerans*. BU initially presents as redness of the skin that is often accompanied with
 51 oedema and swelling. As the disease progresses, oedema may increase or an open ulcer develop (1,
 52 2), the latter is typically characterised by deep undermined edges with a necrotic core comprised of
 53 bacteria, dead skin cells and immune cells (3, 4). Ulcers are predominately found on the extremities
 54 of the body such as the upper (27% of cases) and lower limbs (70% of cases) (5). The disease is rarely
 55 fatal, but if left untreated extensive destruction of subcutaneous tissue can leave victims with
 56 significant deformities and lifelong disabilities (3, 6-9).

57
 58 BU is likely caused when *M. ulcerans* is introduced beneath the skin. This can occur if a region of
 59 contaminated skin surface is punctured or by insertion of an object contaminated with the bacteria
 60 into subcutaneous tissue (e.g. via an insect bite) (10-12). BU-endemic areas include certain regions
 61 of West and Sub-Saharan Africa and south eastern Australia (13, 14).

62
 63 *M. ulcerans* is a slow-growing bacterium, with a doubling time greater than 48 hours (15, 16) making
 64 it difficult for early disease diagnosis as symptoms can take between 4-5 months to appear after
 65 primary infection (17, 18). If diagnosed early, however, BU can be treated effectively by combination
 66 antibiotic therapy (19-21). Unfortunately, in many cases the disease can initially be misdiagnosed
 67 as other, more common skin infections. Additionally, a large proportion of BU cases in African
 68 countries occur in rural villages and poorer areas with limited or no access to health care, with
 69 patients facing disfigurement and permanent disability. Given that diagnoses are delayed and
 70 usually occur after a lesion has become relatively advanced and ulceration extensive (22),
 71 development of an effective BU vaccine to protect those in highly endemic areas is of paramount
 72 importance.

73

74 Currently, the only licensed vaccine against mycobacterial infections approved for human use is the
 75 *M. bovis*-derived Bacille Calmette-Guérin (BCG) vaccine for prevention of tuberculosis. This vaccine
 76 is cross-protective against *M. ulcerans*, but only delays the onset of disease (23-25). Several
 77 experimental vaccines have been tested against *M. ulcerans* infection, as summarised in Table 1.
 78 Although different animal models have been utilised to study *M. ulcerans* infections including
 79 guinea pig, primate, pig and armadillo (10, 23, 26-31), most studies assessing vaccine efficacy have
 80 used mice. Vaccines tested in these murine challenge models have included DNA-based, viral-based,
 81 protein subunit and whole cell vaccines (25, 32-35) (Table 1). Among the various vaccines, BCG
 82 expressing *M. ulcerans* antigens appears to offer the best protective effect against challenge. Hart
 83 et al. (36, 37) showed enhanced protection against BU using a recombinant BCG vaccine that
 84 expressed *M. ulcerans* Ag85A or recombinant Ag85B-EsxH fusion protein in a mouse footpad
 85 challenge model. Whilst improving the immunogenicity of BCG may be a promising route, there are
 86 also some drawbacks; exposure to environmental mycobacteria is believed to decrease the efficacy
 87 of the BCG vaccine and administration in areas where people have been BCG-exposed may be
 88 problematic (38).

89

90 *M. ulcerans* causes disease primarily through the production of a lipid toxin called mycolactone (39).
 91 Mycolactone modulates cell function, in particular secretion of critical cytokines by specifically
 92 inhibiting the Sec61 translocon, enabling *M. ulcerans* to escape host immune defences (40-46). The
 93 toxin is formed from simple acetate and propionate precursors by three polyketide synthases (PKS)
 94 encoded by genes on the plasmid pMUM001 (47, 48). Within each PKS are enzymatic domains that
 95 form the mycolactone molecule. Some of these domains have been found to be immunogenic and
 96 in particular immune responses against the enoyl reductase (ER) domain have previously been
 97 shown to significantly reduce *M. ulcerans* bacterial load in the footpad of a murine prime-boost

vaccination study (49). Based on the immunogenic and protective qualities of ER, we have utilised it as a target antigen for a BU subunit vaccine.

Protein antigens generally require an adjuvant to boost immunogenicity and shape immune responses. A known TLR-2 ligand, R₄Pam₂Cys, has been previously shown to induce robust antibody responses as well as augmented CD4⁺ and CD8⁺ T cell responses, possibly through promoting dendritic cell antigen uptake and trafficking to lymph nodes (50, 51). Given BU is a disease where the bacteria can be both extracellular and intracellular, the ability of R₄Pam₂Cys to robustly engage multiple arms of the adaptive immune system may be beneficial for a BU subunit vaccine.

Previous research has shown that as few as three colony forming units (CFU) of bacteria are required to initiate infection (10), however most animal models challenge with >10⁴ CFU (see Table 1) (25, 32-37, 49, 52-54). This dose is likely to be far higher than the dose of bacteria that leads to natural infection in humans and other animals (10). Such an unrealistic high dose may overwhelm immune responses and underestimate the true efficacy of potential *M. ulcerans* vaccines. For these reasons, we have used a low-dose of *M. ulcerans* in a tail infection challenge model to evaluate an experimental prime-boost subunit vaccine against BU. The experimental subunit vaccine developed here comprised of the *M. ulcerans* mycolactone ER domain protein formulated with the adjuvant, R₄Pam₂Cys. Our murine challenge model with physiologically relevant dosing enabled us to more accurately measure vaccine-induced protection and to explore immune correlates of protection against BU.

Results:

Formulation of the ER-R₄Pam₂Cys subunit vaccine candidate

Mycolactone is the key virulence factor produced by *M. ulcerans* and an attractive vaccine target, but the molecule is poorly immunogenic (55). However, the PKS enzymes used by the bacterium to synthesize mycolactones – are highly conserved and immunogenic (49, 56-58). Therefore, we hypothesized that targeting the conserved enzymatic domains of the mycolactone PKS could be an effective vaccine strategy. One domain in particular, the enoyl reductase (ER) protein domain, elicits serum antibodies in BU patients and healthy controls in BU endemic regions (57). The ER protein expressed as an antigen in a DNA-protein prime-boost vaccine has also been shown to reduce bacterial burden in a mouse footpad *M. ulcerans* challenge model (49). Here, we utilised the ER protein to create a novel BU vaccine candidate by electrostatically associating it with the TLR-2 agonist-based lipopeptide R₄Pam₂Cys. To formulate this vaccine, recombinant 6xHis-tagged ER protein (37 kDa) was first produced and confirmed by SDS-PAGE (Fig. 1A) and western blotting (Fig. 1B). This protein antigen was formulated with R₄Pam₂Cys at various ratios to firstly optimise the formation of protein-lipopeptide complexes. A ratio of 1:1 was sufficient to produce complexes that were larger in size than each constituent on its own (Fig. 1C). While the majority of these complexes were ~300nm in radius (peak 5), the presence of smaller sized particles of ~100nm (peak 4) suggests that not all antigen was incorporated within a complex as this size range corresponds to the size of ER protein (peak 3) or R₄Pam₂Cys alone (peak 2). Although a 1:3 ratio appears to be more effective for the association of these constituents, the size distribution of form complexes was not monodispersed and appeared as two distinct populations (peak 6 and 7). A 1:5 ratio, however, produced a uniform population of complexes that were ~500 nm in radius (peak 8) and this formulation was subsequently used to vaccinate animals.

Evaluation of ER-specific antibody responses in vaccinated mice

To evaluate the ability of the vaccine to induce ER-specific antibody responses, mice were vaccinated, and sera obtained after priming and boosting with the subunit vaccine. Our results showed that primary vaccination with ER + R₄Pam₂Cys resulted in significantly higher levels of ER-specific antibody compared to vaccination with unadjuvanted ER antigen ($p < 0.0001$) (Fig. 1D). In fact, there was no significant difference in responses between unvaccinated mice and those vaccinated with a single dose of ER alone, R₄Pam₂Cys only or BCG. Although a second dose of ER alone was able to increase these responses, the titres were still ~100-fold less than levels achieved by boosting mice with ER + R₄Pam₂Cys ($p < 0.0001$). These results not only indicate that ER-specific antibodies can be generated in mice and that the use of R₄Pam₂Cys can significantly enhance these responses, but that BCG does not induce cross-reactive antibodies to the ER protein.

Characterisation of a low-dose *M. ulcerans* murine tail infection model

We have previously described the use of a low-dose tail infection model for studying insect-mediated transmission of *M. ulcerans* (10). We reasoned that because BU patients were likely to be initially infected with a low bacterial inoculum (10, 11, 59) we could use this model to test the protective efficacy of responses induced by the ER + R₄Pam₂Cys vaccine. This model features the use of a bioluminescent strain of *M. ulcerans* (10, 60) and its infectious characteristics are summarised in Fig. 2. Compared to an uninfected tail (Fig 2A and C), sub-cutaneous infection of a tail results in the appearance of a visible ulcer (Fig 2B) exhibiting the highest levels of bioluminescence concentrated around the centre of the lesion (Fig 2D), i.e. where swelling appears to be the greatest, and beginning to diminish around the periphery reflecting a positive correlation between bacterial burden and light emission (61). Histological cross-sections revealed that while tissue integrity of an uninfected tail appears defined and intact (Fig. 2E & F), dramatic differences are observed in the infected tail, typified by loss of muscle, vasculature and epidermis structure and disruptions to surrounding connective tissue (Fig. 2G & H). Further examination of this tissue

showed the presence of acid-fast bacilli as well as an infiltration of polymorphonuclear cells (PMNs) (Fig. 2I). Despite evidence of bacteria engulfment by these cells (Fig. 2J), it would appear that this response was insufficient for controlling the infection and preventing disease progression.

Monitoring vaccine efficacy using bioluminescent *M. ulcerans* and in vivo imaging system (IVIS)

We have previously established a correlation between *M. ulcerans* bioluminescence and bacterial burden (61). Here, we set a threshold of $\geq 5 \times 10^5$ photons/second (equivalent to 2.8×10^5 CFU) as a measure of ineffective disease control, *i.e.* appearance of disease. Mice were vaccinated subcutaneously and then challenged with an estimated 17 CFU (range 14-20 CFU) of bioluminescent *M. ulcerans* via intradermal tail inoculation. Animals were monitored weekly for changes in bioluminescence using IVIS for up to 24 weeks. Fig. 3A shows an example of the progression of bioluminescence (and therefore disease) in an unvaccinated mouse, up to week 16 whereupon the clinical endpoint of the experiment was reached. Bioluminescence for all mice was recorded across the experimental period. Plots for the different treatment groups show the progression in bioluminescence over time (Fig3B-F). Mice from the ER alone, R₄Pam₂Cys alone and unvaccinated treatment groups displayed the first detectable bioluminescence at week 7. There also appeared to be threshold in bioluminescence, whereby animals expressing $\geq 5 \times 10^5$ photons/second from tail lesions became less able to control the infection and progressed to the clinical endpoint (Fig. 3B). The immune response data for all mice is provided (Supplementary Table S1). Using these data, failure-to-protect was defined as tail bioluminescence equal to or greater than 5×10^5 photons/second at or before week 24 (end of experiment). Therefore, mice were defined as ‘protected’ if bioluminescence was less than 5×10^5 photons/second at week 24.

Vaccination with ER + R₄Pam₂Cys offers similar protection to *M. bovis* BCG vaccine

Survival analysis was conducted to assess vaccine efficacy by measuring the time from infection until tail bioluminescence at the threshold of 5×10^5 photons/second was reached. Mice that reached this threshold were defined as 'not protected'. Significantly less ER + R₄Pam₂Cys vaccinated mice (4/10 animals) developed disease compared to unvaccinated mice (9/10 animals), indicating ER + R₄Pam₂Cys provided some level of protection against disease progression compared to no vaccination (Fig. 3B, E & G) ($p < 0.01$). Mice vaccinated with BCG were best protected with only 1 animal exceeding the bioluminescence threshold (Fig. 3F & G). Although this number of mice was reduced compared to the ER + R₄Pam₂Cys vaccinated animals, the difference was not significant (Fig. 3G). However, the bacterial burden (as indicated by mean photon counts/sec at the clinical endpoint) in BCG vaccinated mice was lower than animals that received the ER + R₄Pam₂Cys vaccine (means: 6×10^5 [n=2, range $3.5 - 8.6 \times 10^5$] versus 3.3×10^7 [n=3, range $2.4 - 4.1 \times 10^7$] photons/sec respectively) suggesting the protective superiority of BCG. There was also no significant difference between the protective efficacy of vaccination with ER alone compared with ER + R₄Pam₂Cys, although mice vaccinated with the latter exhibited delayed disease progression (onset at weeks 16-24) compared to ER vaccinated mice (onset at weeks 8-16) indicating that formulation of the antigen with the R₄Pam₂Cys adjuvant improved immunity (Fig. 3D, E).

Measuring immune parameters following vaccination and challenge

At the experimental end-point, sera, spleens and draining lymph nodes (DLN) from all animals were collected and several parameters were further analysed; ER-specific antibodies, CD4⁺ and CD8⁺ T cells and a panel of 11 murine Th1, Th2 and Th17 cytokines. After *M. ulcerans* challenge, mice vaccinated with ER alone or ER + R₄Pam₂Cys were found to exhibit significantly more ER-specific antibodies than the other treatment groups (Fig 4A) despite not being fully protected. This indicates that, even though the ER protein is highly immunogenic, anti-ER antibodies do not appear to play a major role in controlling infection.

We next investigated if there were any differences in the ability of T cells harvested from the spleens of vaccinated mice to produce cytokines following stimulation with recombinant ER protein (Supplementary Table S1). Our results showed that the numbers of IFN- γ producing CD4⁺ T cells across all vaccine groups did not differ, and in some cases, were higher in unvaccinated mice compared to those vaccinated with ER + R₄Pam₂Cys vaccine group (Fig 4B) indicating that there was no clear correlation between the frequencies of these cells and protection. Similarly, there also did not appear to be any correlation between TNF- α ⁺ CD4⁺ T cells, IFN- γ ⁺ CD8⁺ T cells or TNF- α ⁺ CD8⁺ T cells and protection (Supplementary Table S1).

Comparing levels of cytokine production between vaccine groups also did not clearly identify any cytokines that correlated with protection (see Supplementary Table S1). For example, higher levels of TNF- α were present in the spleens of unvaccinated mice than BCG vaccinated mice (Fig 4C) and even though BCG vaccination resulted in significantly more IFN- γ in draining lymph nodes compared to unvaccinated mice, this was not observed for ER + R₄Pam₂Cys vaccinated mice (Fig 4D).

We therefore based our analysis on comparisons between diseased or protected mice irrespective of the vaccines they received (Fig. 4E,F). Herein, we identified significant increases of IL-2, IL-6, IL-10 IL-17A, IFN- γ , MIP-1b, TNF- α in the lymph nodes of protected mice (Fig. 4F) and significant increases of IFN- γ , IL-6, and TNF- α in the spleens of diseased mice (Fig. 4E). While these data implicate these cytokines as correlates of protection and disease, it did not rank the importance of each cytokine towards either outcome.

Identifying immune responses that predict vaccination outcome

To identify the immune parameters (features) that associate with the response variable ‘vaccine protection’ (here measured as time to reach our bioluminescence detection threshold) independent

of the vaccine used, we conducted a univariate regression analysis using the Cox proportional hazards model. We used this model as it accounts for the fact that a subset of mice (observations) was right-censored, as vaccination outcomes were not measured after 24 weeks post challenge. For each of the 28 immunological features, their association with the response variable (time-to-bioluminescence measured in weeks) was ranked using concordance index (CI) scores. The CI is analogous to the area under the ROC curve, with a CI value of 0.5 indicating a random correlation and 1 indicating a perfect, positive correlation (62). The CI for each univariate regression analysis was used to rank the strength of association for each of the 28 features against the response variable. Using a CI cut-off of 0.70, the top six features were identified as well as the direction of their association with prevention of development of bioluminescence (Table 2). Low levels of IFN- γ and high levels of IL-2 produced in mouse splenocytes were the top two immune parameter features influencing this model, reflected in the individual correlation between their respective titres and time-to-bioluminescence (Fig. 5A, B).

Next, using these top six features, we performed unsupervised machine learning to reveal any structure without the influence of labels, such as arbitrarily imposed bioluminescence thresholds. Here, the data separated into two main clusters. K-means clustering was then applied to assign mice (observations) to the two cluster groups. Inspection of the resulting cluster membership with respect to time to bioluminescence showed a separation of the mice either side of 17 weeks post *M. ulcerans* challenge (Fig. 5C).

Given that the clusters identified through unsupervised learning closely resembled a temporal breakpoint at 17 weeks, we further investigated this binary divide in the data. We used multivariate logistic regression and developed a low-error classifier that could generalize to unseen data, using the underlying structure apparent in the immunological data. We then tested the classifier through

extensive cross-validation. Observations (mice) with bioluminescence above threshold between weeks 8-17 were assigned a '0' and '1' for those with bioluminescence detected in weeks 18-24 or no detection throughout the experiment period. The model included the top six features (Table 2) and was validated through 1,000 random train test splits, with 90% of observations comprising the training groups at each split. The resulting classifier probabilities were used to calculate the area under the ROC curve, AUC = 0.91 (True negatives = 1774, True positives = 2662, False negatives = 120, False positives = 444). The low error and generalizable nature of this classifier demonstrates the existence of a robust structure in the data, in the form of two clusters separated around week 17 (Fig. 5D) and highlights the strong association of the six identified immune parameters with outcome. Most notably here it appears that tissue specific immune responses are important, with a correlation between the appearance of a tail ulcer and evidence of a systemic (spleen) responses and protection correlating with both local (draining lymph nodes) and systemic (spleen) response (Table 2). This association of BU and the production of inflammatory cytokines (IL-6, IFN- γ and TNF) as possible markers of infection, indicated that we could also identify correlates of immune protection against BU.

Assessment of vaccine-specific immune responses

To dissect the immune responses associated with ER + R₄Pam₂Cys vaccination versus BCG and the different controls we noted the differences in the percentage of observations (mice) belonging to specific treatment groups between the two clusters observed above (Fig. 5C) separated by week 17. This summary was reflective of the survival analysis and showed that unvaccinated mice and those that received the adjuvant or ER alone were predominantly in the weeks 8-17 cluster, while ER + R₄Pam₂Cys and BCG-vaccinated mice were predominantly in the weeks 18-24 cluster (Fig. 5E). In order to obtain the individual immune profile of the different treatment groups, group-specific univariate logistic regression analyses were undertaken. Here, the response variable was coded as

a '1' for membership in a particular group and '0' for membership in all other groups. Analyses were conducted for each of the five treatment groups and the model coefficient weights were used to determine both the strength and direction of association of each feature with that of each treatment group. The resulting *p*-values from the model coefficients were used to assess significance of the associations (Fig. 5F, Supplementary Table S2). The combination of the ER antigen and R₄Pam₂Cys together were important for inducing protective responses that associated with local production of IL-4, IL-2, IL-17A in the DLN, in addition to ER-specific antibody responses. Neither ER antigen or R₄Pam₂Cys alone induced this profile and protection using the former was only linked to ER- but not *M. ulcerans*-specific antibody responses (post-challenge timepoints). In comparison, BCG vaccination-mediated protection was associated with a greater breadth of localised cytokines responses than ER + R₄Pam₂Cys, with higher IL-6, TNF- α and MIP-1 β in the DLN. Of note, evidence of systemic inflammation, such as IL-17A and IFN- γ in the spleen was associated with poorer BCG performance.

Discussion

In this study, we investigated various immune parameters induced by the use of BCG and an experimental subunit vaccine against BU and sought to identify immune correlates associated with protection in a mouse tail infection model. Studies have shown that the tail is a suitable location for infection as BU predominantly affects extremities (11, 52, 63) and in combination with the use of bioluminescent *M. ulcerans*, offers several advantages over footpad, hock or ear infections used in most BU vaccine studies (as shown in Table 1 and (64)). Tail infections are less likely to affect mouse mobility, or cause rapid tissue loss and may also prevent added trauma, inflammation or secondary infections at the challenge site (65). A key feature of this model also allows the use of a significantly lower bacterial challenge dose compared to other studies (approximately 14-20 CFU compared to 10⁴-10⁶ CFU) (25, 32-37, 49, 52-54) (Table 1) and enables measuring bacterial growth in the same

animal over time. This lower dose is likely to be more physiologically relevant, in terms of reflecting the bacterial inoculum that occurs during *M. ulcerans* transmission to humans (10, 11, 59). Sporadic healing of BU disease was also seen in this model, an observation that has been noted in humans and other animals (29, 66-68).

Vaccination with the ER + R₄Pam₂Cys formulation resulted in protection of 60% of mice from BU challenge. Although more of these vaccinated mice reached our defined disease outcome after 24 weeks compared to BCG-vaccinated mice, the difference was not statistically significant. There was also no significant difference in the number of mice displaying any bioluminescence between each group. The fact that ER + R₄Pam₂Cys was significantly more protective than vaccination with R₄Pam₂Cys alone indicates any non-antigen specific triggering of innate immune responses by this adjuvant (69, 70) (71) was not sufficient for conferring long-lasting protection and the inclusion of the ER protein was necessary to achieve any protective effects. This was further evident by vaccinating with ER alone. Despite not seeing any clear significant differences in the clinical outcomes at the end of the trial when compared to ER + R₄Pam₂Cys vaccination, the inclusion of R₄Pam₂Cys delayed disease onset by ~8 weeks and correlated with the induction of significantly more ER-specific antibodies after a primary and booster vaccination.

The presence of these antibodies was nonetheless insufficient to provide total protection against *M. ulcerans* challenge. This is perhaps not unexpected given that other studies have also reported little correlation between strong BU antibodies and protection, in mice (34) or sera of BU patients (57, 72). To identify other immune correlates associated with the protective effects observed in our study, a Cox proportional hazards regression model was utilized. Here, the univariate analyses allowed us to identify the top six features that most strongly associated with differences in time to detection of bioluminescence. These models assume normalized data, and although we cannot infer

how much an increase or decrease in units could affect the clinical outcome, we are able to rank each factor based on its contribution to either disease or protection. This model also considers the effect of each factor in delaying the onset of disease rather than just modelling through a binary ‘protected’ or ‘diseased’ outcome. Similar regression modelling has been described to predict outcomes for tuberculosis patients after treatment, effect of hospital-acquired *Clostridium difficile* on hospital stay and survival of *Staphylococcus aureus* in milk (73-75). The model assumes that eventually all mice will succumb to disease and due to the constraints in our data, it cannot determine threshold levels of cytokines that will predict disease outcomes.

The cytokines most associated with protection in BCG mice were different to those identified in mice vaccinated with ER+R₄Pam₂Cys, which is not surprising given that BCG is a multi-antigen live-attenuated vaccine and thus likely to utilise both common and distinct protective responses and mechanisms to those induced by our vaccine candidate.

Through multivariate logistic regression modelling we identified the presence of IL-2 in the spleen and lymph nodes as markers that were most strongly associated with protection. Although there are no studies that directly link IL-2 with protection against *M. ulcerans*, it plays a key role in the differentiation, proliferation and maintenance of T cell responses (76). Therefore, it is perhaps not surprising that its role in this murine model is likely to be important for the induction of protective adaptive immunity against *M. ulcerans*.

However, our results did not show any correlation between levels of cytokine producing CD4⁺ and CD8⁺ T cells and protection in vaccinated groups despite studies that have shown them to play a role in BU control (77, 78). In particular, *M. ulcerans*-specific CD4⁺ T cells have been found to migrate to the site of infection from draining lymph nodes early in infection but are depleted as the infection

persists (77), an effect that could be attributed to the ability of the *M. ulcerans* exotoxin mycolactone to impair T cell and macrophage function (41, 44, 78).

In addition, we also identified the presence of systemic IL-6, TNF- α and IFN- γ (in the spleen) to be strongly associated with disease. IL-6 is a pro-inflammatory cytokine produced by many cell types in response to pathogens and is linked to the production of TNF- α , both of which can be detected in BU lesions and serum of BU patients (78, 79) (80). TNF- α in particular, plays a key role in inflammatory cell recruitment and in conjunction with IFN- γ , increases the phagocytic ability of macrophages to enhance killing of mycobacteria (81, 82). However many studies have shown that mycolactone suppresses TNF- α production by T cells and especially macrophages (83, 84), decreasing their ability to control BU infection (85).

IFN- γ itself has also been shown to be important for controlling *M. ulcerans* infection as IFN- γ deficient mice cannot prevent the onset of disease (86). It is also detected at high levels in patients with both developed ulcers and early lesions (87) and healed ulcers (88) where it is believed to mediate macrophage function (89) and drive iNOS expression to facilitate bacterial killing (90). Altogether, the fact that these cytokines are elevated at a systemic level in the diseased animals in our study but not in lymph nodes draining from the tail suggests that their activity is being dampened at the site of infection. These effects do not appear to be present in protected animals where increased levels of cytokines are detected in the draining lymph node and not the spleen. In fact, the localised, but not systemic presence, of these and other cytokines including IL17A, MIP1b and IL10 are strongly associated with protection.

Although most of the immunosuppression during BU infection can be attributed to mycolactone, chronic inflammation can also be key driver as noted by the increased splenic cytokine levels. Many

cell types have been implicated as the cause of immunosuppression in cancers, chronic viral infections (such as HCV, HIV, HBV) and even *M. tuberculosis* infection. These include myeloid-derived suppressor cells (MDSCs) (91) regulatory T cells (T_{reg}) (92) and T helper 17 (T_h17) (93), which can suppress effector T cell function and inhibit NK and dendritic cell activity through direct cell-to-cell interactions or the production of immunosuppressive cytokines. MDSCs in particular can be recruited by IFN- γ (94) and IL-6 (95), both of which are found in higher levels in our unprotected mice. On the other hand, while T_h17 cells are crucial for the control of infection, especially extracellular bacterial and fungal infections, elevated frequencies can lead to tissue inflammation alongside matrix destruction, autoimmunity and vascular activation (96). The observation that higher systemic IL-17A correlates with the lack of protection suggests that these cells play a role in determining BU disease outcomes.

Tissue changes due to chronic infection could also play a compounding effect on the severity of BU disease outcomes. Our histological analysis of BU-infected tail tissue showed a loss of muscle and epidermis, changes in connective tissue and loss of vasculature which may explain why lymphocytes and other immune cells are unable to access the sites of greatest infection and tissue damage. BU tissue necrosis can also extend some distance from the site of bacterial colonisation, an observation that led to the identification of mycolactone as the cause of coagulative necrosis (39, 97, 98). Mycolactone has been well described as causing cell death to skin-resident cells such as fibroblasts, adipocytes, keratinocytes and endothelial cells (39, 99, 100). Primary human dermal microvascular endothelial cells are especially sensitive to mycolactone and after exposure lose their ability to activate a key anticoagulant protein (protein C) after exposure, causing a reduction in intravascular fluidity and preventing immune cell infiltration to the infection site (99). Thus, the combination of immunosuppressive immune host responses and tissue destruction, in conjunction with

mycolactone at the site of infection, may increase the risk for poorer disease outcomes for those chronically infected with BU.

Although we have identified several factors associated with disease and protection, our results provide impetus to further expand these profiles and establish their importance. For example, changes in cytokines levels before challenge and throughout the infection phase could be monitored and integrated into models, as well as analysing frequencies of various other innate- and adaptive-immune cell populations and identifying those that produce cytokines of interest. In evaluating and demonstrating that a subunit vaccine can protect against BU in our mouse challenge model, albeit not as efficacious as BCG, our results showed that protection can be mediated through different immune mechanisms. Disease progression was also commonly linked to the presence of pro-inflammatory cytokines in the spleen and not the lymph node. These profiles indicate that localised and not systemic responses are more important for conferring protection and also provide a template that could guide the design and development of novel vaccination strategies against BU.

Finally, we conclude that the mycolactone biosynthesis pathway constitutes a viable vaccine target to protect against *M. ulcerans*. As *M. ulcerans* is slow-growing and requires its highly conserved mycolactone PKS for virulence, the development of resistance is unlikely. As such, approaches based on the use of multiple PKS enzymatic domains may prove even more efficacious. Moreover, studies that have introduced *M. ulcerans* and *M. marinum*-specific proteins into BCG have been shown to increase its protective effect. Collectively, this demonstrates the additive power of using a broader suite of antigens and the potential for a viable vaccine against BU.

Methods:

Strains and culture conditions.

444 *Escherichia coli* ClearColi©BL21 (DE3) containing the plasmid, pJexpress-ER (strain TPS847) was
 445 grown at 37°C in Luria-Bertani (LB) broth (Difco, Becton Dickinson, MD, USA) supplemented with
 446 100 µg/ml ampicillin (Sigma-Aldrich, USA) to express the enoyl reductase (ER) protein (57). Log-
 447 phase bioluminescent *Mycobacterium ulcerans* (strain JKD8049 containing integrated plasmid
 448 pMV306 *hsp:luxG13*) (10, 60) was grown at 30°C in 7H9 broth or 7H10 agar (Middlebrook, Becton
 449 Dickinson, MD, USA) supplemented with oleic acid, albumin, dextrose and catalase growth
 450 supplement (OADC) (Middlebrook, Becton Dickinson, MD, USA), 0.5% glycerol (v/v) and 25 µg/ml
 451 kanamycin (Sigma-Aldrich, USA). *M. bovis* BCG (strain 'Danish 1331') used for vaccinations was
 452 grown at 37°C in 7H9 broth or 7H10 agar supplemented with OADC. Mycobacterial colony counts
 453 from cultures or tissue specimens were performed using spot plating as previously described (10).
 454 All culture extracts were screened by LC-MS for the presence of mycolactones as previously
 455 described to ensure bacteria used in transmission experiments remained fully virulent (101).

456

457 *Recombinant protein expression*

458 Overnight culture of *E. coli* TPS847 was diluted to OD₆₀₀ = 0.05 in LB broth. The culture was incubated
 459 at 37°C with shaking at 200 rpm until OD₆₀₀ = 0.6-0.7, followed by the addition of 1 mM IPTG
 460 (Isopropyl b-D-1-thiogalactopyr-anoside) to induce protein expression for a further four hours. Cells
 461 were then resuspended in wash buffer (8 M urea, 150 mM sodium chloride, 10% glycerol) and
 462 sonicated at amplitude 60 (QSonica Ultrasonic Liquid Processor S-4000, Misonix) until the solution
 463 turned clear. The lysate was filtered with a 0.22 µm filter (Millipore) to remove cellular debris and
 464 protein was column-purified using anti-histidine resin (ClonTech). The resin was washed with wash
 465 buffer which was gradually replaced with tris buffer (20 mM Tris-HCl, 150 mM sodium chloride, 10%
 466 glycerol) over ten washes followed by two washes with tris buffer containing 20 mM imidazole.
 467 Protein was eluted in tris buffer containing 200 mM imidazole and dialysed in phosphate buffered
 468 saline (PBS) before concentration using a microcon column (Millipore). Proteins were tested for

endotoxin contamination using Pierce™ limulus amoebocyte lysate assay (Thermo Scientific™) and relative size was confirmed by sodium dodecyl sulphate polyacrylamide gel electrophoresis.

Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)

Samples were denatured in an equal volume of 2 x sample loading buffer (40% (v/v) 0.5M Tris-HCL pH6.8, 10% glycerol, 1.7% (w/v) SDS, 10% 2-B-mercaptoethanol, 0.13% (w/v) bromophenol blue in distilled water) at 100°C for 5 minutes. Ten microlitres of each sample and SeeBlue® Plus2 pre-stained protein standard (Invitrogen) was loaded onto a 0.5mm 12% polyacrylamide gel under reducing conditions, as previously described (102). The gel was run in buffer containing 0.3% (w/v) Tris, 1.44% (w/v) glycine and 0.1% (w/v) SDS in distilled water for 1 hour at 150 volts (Mini-protean vertical electrophoresis cell, Bio-Rad), stained in Coomassie stain (45% methanol, 10% acetic acid 0.25% (w/v) Coomassie brilliant blue in distilled water) for 1 hour and destained in Coomassie destain (33% Methanol, 10% acetic acid, 60% distilled water) until protein bands were visualised.

Western Blotting

Protein separated on a 12% polyacrylamide gel was transferred to a nitrocellulose membrane in a tris-glycine transfer buffer (1.5 mM Tris, 12mM glycine, 15 % methanol (v/v) in distilled water) for 1 hour at 100 volts (Mini Trans-Blot Cell, Bio-Rad) and incubated in blocking buffer (5% (w/v) skim milk powder and 0.1% Tween-20 in PBS) overnight at 4°C. The membrane was then incubated with anti6xHIS-HRP antibody (Roche Applied Science, USA) at 1:500 dilution for 2 hours and washed in PBS containing 0.1% Tween-20 prior to exposure to developing solution (Western Lighting Chemiluminescence kit, Perkin Elmer, USA) according to the manufacturer's guidelines. Chemiluminescence was detected using an MF ChemiBIS gel imaging system (DNR Bio-Imaging Systems, Israel).

Particle size analysis of protein antigen and lipopeptide formulations by dynamic light scattering (DLS)

The association between protein and R₄Pam₂Cys was measured using dynamic light scattering (DLS) by mixing 5 µg of protein with increasing amounts of lipopeptide in 50 µl PBS. The size distribution of particles in solution (presented as hydrodynamic radius) were measured in 4µl of cyclin olefin co-polymer cuvettes using a DynaPro NanoStar DLS instrument (Wyatt Technology, CA, USA) equipped with 658nm laser with a scattering angle of 90°. Measurements were acquired in triplicate with each measurement consisting of 30 readings at 5 second intervals at 25°C. Data was analysed using Dynamics software (v7.1.7.16).

Vaccination of animals

The synthesis and purification of the branched cationic lipopeptide, R₄Pam₂Cys, was performed as previously described (103, 104). Each vaccine dose contained 25 µg protein formulated in PBS with R₄Pam₂Cys at a 1:5 molar ratio of protein to lipopeptide in a final volume of 100 µl. Live-attenuated *M. bovis* BCG strain 'Danish 1331' was grown to log phase and stored at -80°C in 20% glycerol until used. Bacteria were washed with PBS and resuspended in 200ul, before administration at 4.7 x 10⁵ bacteria per dose. All vaccines and control formulations were sonicated for 5 minutes in a waterbath sonicator before being administered.

Female 6-week old BALB/c mice were sourced from ARC (Canning Vale, Australia) and housed in individual ventilated cages. Food and water were given *ad libitum*. Experiments were approved by The University of Melbourne Animal Ethics Committee (Approval identification number: 1613870). For vaccination using R₄Pam₂Cys, animals were inoculated subcutaneously at the base of tail (100µl per dose at 50 µl per flank) and boosted 21 days later with the same formulations. Mice vaccinated

with *M. bovis* BCG were given one dose subcutaneously in a similar manner (200 µl per dose at 100µl per flank). There were 10 mice in each vaccination group.

M. ulcerans challenge

Mice were challenged with bioluminescent *M. ulcerans* on day 35 as described previously (10). Briefly, tails of isoflurane anaesthetised mice were dipped in 7H9 culture containing log-phase bioluminescent *M. ulcerans* bacteria (concentration 1.27×10^6 CFU/mL (range: 1.07×10^6 – 1.46×10^6 CFU). Contaminated tails were then pierced once subcutaneously with a sterile 25-G needle. The infectious dose was calculated to be 17 CFU (range: 14-20) using methods previously described (10). Mice were allowed to recover and monitored for up to 24 weeks after infection and sacrificed when tail ulceration was observed wherein spleens, lymph nodes and sera were harvested for immunological analysis.

IVIS imaging

Infected mice were imaged weekly from 6-weeks post-infection to detect the emission of bioluminescence. Images were captured using the Lumina XRS Series III In Vitro Imaging System (IVIS®) (Perkin Elmer, MA, USA) and Living Image Software v3.2 with the following settings: Field of View 24, relative aperture $f'1.2$, medium binning, 60s exposure. Bioluminescence was calculated using Living Image Software v3.2.

Serum antibody titre measurements

Serum antibody titres were measured by enzyme linked immunosorbent assay (ELISA) (105) using plates (Nunc, Thermo Scientific) that were previously coated with antigen overnight, either purified recombinant ER protein or heat-killed whole cell *M. ulcerans* lysate. The presence of bound antibodies were detected by incubating serum-exposed wells with horse radish peroxidase

conjugated rabbit anti-mouse IgG (Dako, Glostrup, Denmark) for 2 hours followed by the addition of the enzyme substrate (0.2mM ABTS in 50mM citric acid containing 0.004% hydrogen peroxide and left to develop for 10-15 minutes before the addition of 50nM sodium fluoride to stop the reaction. Plates were read at dual wavelengths of 505 and 595 nm on plate reader (LabSystems Multiskan Multisoft microplate reader) and antibody titres expressed as the reciprocal of the highest dilution of serum required to achieve an optical density of 0.2.

Intracellular cytokine staining

Single cell suspensions were derived from the spleen and draining lymph nodes and resuspended in RP10 media (RPMI 1640 (Sigma) supplemented with 10% foetal bovine serum (Gibco, ThermoFisher Scientific, Waltham, MA USA), 2mM L-glutamine, 1mM sodium pyruvate, 55 μ M 2-mercaptoethanol, 12 μ g gentamycin, 100 U/ml penicillin and 100 μ g/ml streptomycin). Spleen and lymph node-derived cells were cultured in 96-well plates (CoStar, Corning, USA) at 1×10^7 cells/per well and 1×10^5 cells/well, respectively 200 μ l of RP10 containing 10 U/ml IL-2 (Roche, Mannheim, Germany), 1 μ g/ml plate-bound anti-CD28 (BD Pharmingen, Becton Dickinson, Clone 37.51) and 20 μ g/ml ER protein for 12 hours at 37°C in 5% CO₂. Golgiplug (1 μ g/ml) (Becton Dickinson) was added for the last 4 hours of incubation. Cells were then stained with 7AAD-Live/Dead stain dye (Biolegend, CA, USA), BV510-anti-B220 (BD Horizon, Becton Dickinson, Clone RA3-6B2), BV605-antiCD4 (Biolegend, Clone RM4-5), APC-Cy7-anti-TCRb (BD Pharmingen, Clone H57-597) and PE-Cy7-anti-CD8 (BD Pharmingen, Clone 53-6.7) anti-mouse monoclonal antibodies at 4°C in the dark. Intracellular staining was performed by fixing cells with Cytofix/Cytoperm solution (Becton Dickinson, USA) followed by permeabilisation and intracellular staining with Perm/Wash buffer (Becton Dickinson) and BV786-IFN- γ (BD Horizon, Clone XM G1.2), AF647-IL-17A (BD Pharmingen, Becton Dickinson, Clone TCII-18H10) and PE-TNF- α (BD Biosciences, Clone MP6-XT22) antibodies

for 30 minutes at 4°C before analysis on an LSR Fortessa flow cytometer (BD Biosciences, US). Data analyses were performed using FlowJo (Tree Star, OR, USA).

Cytokine Bead Array

Spleen and lymph node-derived cells were incubated in 500 µl RP10 supplemented with 25 µg/ml ER protein for 72 hours at 37°C in 5% CO₂. Supernatant was collected and a cytokine bead array was performed using a mouse flex set (BD Biosciences, USA) to detect IL-2, IL-4, IL-6, IL-10, IL-12/IL-23p40, IL-17, IFN-γ, TNF, MCP-1, MIP1α, MIP1β as per the manufacturer's instructions. Samples were acquired using a FACSCanto II flow cytometer (BD Biosciences) and cytokine quantities calculated using FCAP Array™ Software v3.0.

Histology and microscopy

Tail tissues from the site of infection were fixed in PBS containing 10% non-buffered formalin then embedded in paraffin and sliced into 10 µM thick segments. The sliced segments were Ziehl Neelsen- or H&E-stained prior to microscope imaging. Images of tail segments were captured using a light microscope (Olympus BX53 Light microscope, Olympus-Life Science).

Statistical analysis

GraphPad Prism software (GraphPad Software v7, CA, USA) was used to perform statistical analyses on the antibody titre, time to luminescence, T cell numbers and cytokine titre data. Antibody titres were analysed using one-way ANOVA with Tukey's correction for multiple comparisons. The time to bioluminescence data was displayed as a Kaplan-Meier plot and differences determined using a Log-Rank (Mantel-Cox) test. Mann-Whitney tests were performed to compare cytokine titres between protected and diseased mice and for comparisons between vaccination groups. All tests were conducted at the 5% significance level.

592

593 *Statistical modelling*

594 Twenty-eight data features (*i.e.* the immune parameters measured in each mouse, refer to Table
595 S1) were transformed using the R package *bestNormalize* (106). Transformed features were then
596 normalised (between 0 and 1 for each feature) using the *MinMaxScaler* function of *Scikit-learn*
597 (107). As many of the vaccination outcome observations (time-to-bioluminescence) were right-
598 censored, we employed the Cox proportional hazards regression analysis using the *Scikit-survival*
599 module of *Scikit-learn* in Python (108). Here, univariate analyses were run for each of the 28 features
600 using the continuous response variable of time-to-bioluminescence. The standard metric for
601 assessing the predictive performance of a survival model is the concordance index (CI) (62, 109,
602 110). A CI >0.7 was used to identify the top six features of this model. Unsupervised learning and
603 data dimensionality reduction is an ideal way to identify structure in continuous data without the
604 influence of labels. The method of *t-Distributed Stochastic Neighbor Embedding* (t-SNE) is a
605 dimensionality reduction technique that retains both the global structure and local layout of the
606 high-dimensional data through exchanging the Euclidean distances between all pair of data points
607 into heavy-tailed conditional probabilities (111). This method is advantageous over conventional
608 principal component analysis (PCA), as it does not rely on a linear assumption and can capture
609 nonlinear relationships (111). We explored the data, independent of labels, by reducing the top six
610 features obtained from the Cox proportional hazards regression analysis to a two-dimensional space
611 using the t-SNE package in *Scikit-learn* (107) . The two clusters detected through visual inspection
612 were objectively defined, with observations assigned to two groups using K-means clustering, as
613 implemented in *Scikit-learn* (107). A multivariate logistic regression classifier was then built using
614 the top six features, with the two clusters identified by *t-SNE* as the response variables. To reduce
615 the possibility of over-fitting, the model was validated through 1,000 random train-test splits, in
616 which 90% of the observations made up each training set. These models were built using the logistic

617 regression classifier as implemented in *Scikit-learn* (107) and Receiver-Operator-Characteristic
618 curves were used to evaluate model performance (112). In order to assess the immune features
619 that were associated with different vaccination groups, a univariate logistic regression analysis was
620 then conducted for each group using *R* (112). The estimated model coefficients were used to assess
621 the direction and strength of the association, and the corresponding p-value used to determine
622 statistical significance at the 5% significance level.

Acknowledgments: We thank Laura Leone for expert assistance with histology. This research was supported by the National Health and Medical Research Council, Australia (GNT1008549). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

References:

1. Guarner J, Bartlett J, Whitney EA, Raghunathan PL, Stienstra Y, Asamo K, Etuaful S, Klutse E, Quarshie E, van der Werf TS, van der Graaf WT, King CH, Ashford DA. 2003. Histopathologic features of *Mycobacterium ulcerans* infection. *Emerg Infect Dis* 9:651-656.
2. Vincent QB, Ardant MF, Adeye A, Goundote A, Saint-Andre JP, Cottin J, Kempf M, Agossadou D, Johnson C, Abel L, Marsollier L, Chauty A, Alcais A. 2014. Clinical epidemiology of laboratory-confirmed Buruli ulcer in Benin: a cohort study. *Lancet Glob Health* 2:e422-30.
3. Hayman J, McQueen A. 1985. The pathology of *Mycobacterium ulcerans* infection. *Pathology* 17:594-600.
4. Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, Filho AL, Milanezi F, Schmitt FC, Meyers WM, Portaels F, Silva MT, Pedrosa J. 2005. Infection with *Mycobacterium ulcerans* induces persistent inflammatory responses in mice. *Infect Immun* 73:6299-310.
5. Yerramilli A, Tay EL, Stewardson AJ, Kelley PG, Bishop E, Jenkin GA, Starr M, Trevillyan J, Hughes A, Friedman ND, O'Brien DP, Johnson PDR. 2017. The location of Australian Buruli ulcer lesions-Implications for unravelling disease transmission. *PLoS Negl Trop Dis* 11:e0005800.
6. van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K. 1999. *Mycobacterium ulcerans* infection. *Lancet* 354:1013-8.
7. Pszolla N, Sarkar MR, Strecker W, Kern P, Kinzl L, Meyers WM, Portaels F. 2003. Buruli ulcer: a systemic disease. *Clin Infect Dis* 37:e78-82.
8. Loftus MJ, Tay EL, Globan M, Lavender CJ, Crouch SR, Johnson PDR, Fyfe JAM. 2018. Epidemiology of Buruli Ulcer Infections, Victoria, Australia, 2011-2016. *Emerg Infect Dis* 24:1988-1997.
9. Toll A, Gallardo F, Ferran M, Gilaberte M, Iglesias M, Gimeno JL, Rondini S, Pujol RM. 2005. Aggressive multifocal Buruli ulcer with associated osteomyelitis in an HIV-positive patient. *Clin Exp Dermatol* 30:649-51.
10. Wallace JR, Mangas KM, Porter JL, Marcsisin R, Pidot SJ, Howden B, Omansen TF, Zeng W, Axford JK, Johnson PDR, Stinear TP. 2017. *Mycobacterium ulcerans* low infectious dose and mechanical transmission support insect bites and puncturing injuries in the spread of Buruli ulcer. *PLoS Negl Trop Dis* 11:e0005553.
11. Marsollier L, Robert R, Aubry J, Saint Andre JP, Kouakou H, Legras P, Manceau AL, Mahaza C, Carbonnelle B. 2002. Aquatic insects as a vector for *Mycobacterium ulcerans*. *Appl Environ Microbiol* 68:4623-8.
12. Meyers WM, Shelly WM, Connor DH, Meyers EK. 1974. Human *Mycobacterium ulcerans* infections developing at sites of trauma to skin. *Am J Trop Med Hyg* 23:919-23.

- 665 13. Buultjens AH, Vandelannoote K, Meehan CJ, Eddyani M, de Jong BC, Fyfe JAM, Globan M,
666 Tobias NJ, Porter JL, Tomita T, Tay EL, Seemann T, Howden BP, Johnson PDR, Stinear TP.
667 2018. Comparative Genomics Shows That *Mycobacterium ulcerans* Migration and
668 Expansion Preceded the Rise of Buruli Ulcer in Southeastern Australia. Appl Environ
669 Microbiol 84.
- 670 14. Simpson H, Deribe K, Tabah EN, Peters A, Maman I, Frimpong M, Ampadu E, Phillips R,
671 Saunderson P, Pullan RL, Cano J. 2019. Mapping the global distribution of Buruli ulcer: a
672 systematic review with evidence consensus. Lancet Glob Health 7:e912-e922.
- 673 15. Stinear TP, Seemann T, Pidot S, Frigui W, Reyssset G, Garnier T, Meurice G, Simon D,
674 Bouchier C, Ma L, Tichit M, Porter JL, Ryan J, Johnson PD, Davies JK, Jenkin GA, Small PL,
675 Jones LM, Tekai F, Laval F, Daffe M, Parkhill J, Cole ST. 2007. Reductive evolution and
676 niche adaptation inferred from the genome of *Mycobacterium ulcerans*, the causative
677 agent of Buruli ulcer. Genome Res 17:192-200.
- 678 16. Marsollier L, Stinear T, Aubry J, Saint Andre JP, Robert R, Legras P, Manceau AL, Audrain C,
679 Bourdon S, Kouakou H, Carbonnelle B. 2004. Aquatic plants stimulate the growth of and
680 biofilm formation by *Mycobacterium ulcerans* in axenic culture and harbor these bacteria
681 in the environment. Appl Environ Microbiol 70:1097-103.
- 682 17. Loftus MJ, Trubiano JA, Tay EL, Lavender CJ, Globan M, Fyfe JAM, Johnson PDR. 2018. The
683 incubation period of Buruli ulcer (*Mycobacterium ulcerans* infection) in Victoria, Australia -
684 Remains similar despite changing geographic distribution of disease. PLoS Negl Trop Dis
685 12:e0006323.
- 686 18. Trubiano JA, Lavender CJ, Fyfe JA, Bittmann S, Johnson PD. 2013. The incubation period of
687 Buruli ulcer (*Mycobacterium ulcerans* infection). PLoS Negl Trop Dis 7:e2463.
- 688 19. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, Adentwe E, Lartey A, Tetteh I,
689 Wansbrough-Jones M. 2010. Clinical efficacy of combination of rifampin and streptomycin
690 for treatment of *Mycobacterium ulcerans* disease. Antimicrob Agents Chemother 54:3678-
691 85.
- 692 20. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, Awua-Boateng
693 NY, Ampadu EO, Siegmund V, Schouten JP, Adjei O, Bretzel G, van der Werf TS. 2010.
694 Antimicrobial treatment for early, limited *Mycobacterium ulcerans* infection: a randomised
695 controlled trial. Lancet 375:664-72.
- 696 21. Wadagni AC, Barogui YT, Johnson RC, Sopoh GE, Affolabi D, van der Werf TS, de Zeeuw J,
697 Kleinnijenhuis J, Stienstra Y. 2018. Delayed versus standard assessment for excision surgery
698 in patients with Buruli ulcer in Benin: a randomised controlled trial. Lancet Infect Dis
699 18:650-656.
- 700 22. Zingue D, Bouam A, Tian RBD, Drancourt M. 2018. Buruli Ulcer, a Prototype for Ecosystem-
701 Related Infection, Caused by *Mycobacterium ulcerans*. Clin Microbiol Rev 31.
- 702 23. Tanghe A, Adnet PY, Gartner T, Huygen K. 2007. A booster vaccination with *Mycobacterium*
703 *bovis* BCG does not increase the protective effect of the vaccine against experimental
704 *Mycobacterium ulcerans* infection in mice. Infect Immun 75:2642-4.
- 705 24. Converse PJ, Almeida DV, Nuermberger EL, Grosset JH. 2011. BCG-mediated protection
706 against *Mycobacterium ulcerans* infection in the mouse. PLoS Negl Trop Dis 5:e985.
- 707 25. Fraga AG, Martins TG, Torrado E, Huygen K, Portaels F, Silva MT, Castro AG, Pedrosa J.
708 2012. Cellular immunity confers transient protection in experimental Buruli ulcer following
709 BCG or mycolactone-negative *Mycobacterium ulcerans* vaccination. PLoS One 7:e33406.
- 710 26. Walsh DS, Dela Cruz EC, Abalos RM, Tan EV, Walsh GP, Portaels F, Meyers WM. 2007.
711 Clinical and histologic features of skin lesions in a cynomolgus monkey experimentally
712 infected with *Mycobacterium ulcerans* (Buruli ulcer) by intradermal inoculation. Am J Trop
713 Med Hyg 76:132-4.

27. Ortiz RH, Leon DA, Estevez HO, Martin A, Herrera JL, Romo LF, Portaels F, Pando RH. 2009. Differences in virulence and immune response induced in a murine model by isolates of *Mycobacterium ulcerans* from different geographic areas. Clin Exp Immunol 157:271-81.
28. Bolz M, Ruggli N, Ruf MT, Ricklin ME, Zimmer G, Pluschke G. Experimental infection of the pig with *Mycobacterium ulcerans*: a novel model for studying the pathogenesis of Buruli ulcer disease.
29. Marion E, Jarry UA-Ohoo, Cano C, Savary CA-Ohoo, Beauvillain CA-Ohoo, Robbe-Saule M, Preisser L, Altare F, Delneste Y, Jeannin P, Marsollier L. FVB/N Mice Spontaneously Heal Ulcerative Lesions Induced by *Mycobacterium ulcerans* and Switch M. *ulcerans* into a Low Mycolactone Producer.
30. Benard AA-OhooX, Sala C, Pluschke G. *Mycobacterium ulcerans* Mouse Model Refinement for Pre-Clinical Profiling of Vaccine Candidates.
31. Walsh DS, Meyers Wm Fau - Krieg RE, Krieg Re Fau - Walsh GP, Walsh GP. Transmission of *Mycobacterium ulcerans* to the nine-banded armadillo.
32. Tanghe A, Content J, Van Vooren JP, Portaels F, Huygen K. 2001. Protective efficacy of a DNA vaccine encoding antigen 85A from *Mycobacterium bovis* BCG against Buruli ulcer. Infect Immun 69:5403-11.
33. Tanghe A, Dangy JP, Pluschke G, Huygen K. 2008. Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from *Mycobacterium ulcerans* by homologous protein boosting. PLoS Negl Trop Dis 2:e199.
34. Bolz M, Benard A, Dreyer AM, Kerber S, Vettiger A, Oehlmann W, Singh M, Duthie MS, Pluschke G. 2016. Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of *Mycobacterium ulcerans* Induces Antibodies but Fails to Provide Protection against Buruli Ulcer. PLoS Negl Trop Dis 10:e0004431.
35. Hart BE, Hale LP, Lee S. 2016. Immunogenicity and protection conferred by a recombinant *Mycobacterium marinum* vaccine against Buruli ulcer. Trials in Vaccinology 5:88-91.
36. Hart BE, Hale LP, Lee S. 2015. Recombinant BCG Expressing *Mycobacterium ulcerans* Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer. PLoS Negl Trop Dis 9:e0004046.
37. Hart BE, Lee S. 2016. Overexpression of a *Mycobacterium ulcerans* Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy. PLoS Negl Trop Dis 10:e0005229.
38. Gowthaman U, Mushtaq K, Tan AC, Rai PK, Jackson DC, Agrewala JN. 2015. Challenges and solutions for a rational vaccine design for TB-endemic regions. Crit Rev Microbiol 41:389-98.
39. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, Lee R, Small PL. 1999. Mycolactone: a polyketide toxin from *Mycobacterium ulcerans* required for virulence. Science 283:854-7.
40. Ogbechi J, Hall BS, Sbarrato T, Taunton J, Willis AE, Wek RC, Simmonds RE. 2018. Inhibition of Sec61-dependent translocation by mycolactone uncouples the integrated stress response from ER stress, driving cytotoxicity via translational activation of ATF4. Cell Death & Disease 9:397.
41. Baron L, Paatero AO, Morel JD, Impens F, Guenin-Mace L, Saint-Auret S, Blanchard N, Dillmann R, Niang F, Pellegrini S, Taunton J, Paavilainen VO, Demangel C. 2016. Mycolactone subverts immunity by selectively blocking the Sec61 translocon. J Exp Med 213:2885-2896.
42. Coutanceau E, Decalf J, Martino A, Babon A, Winter N, Cole ST, Albert ML, Demangel C. 2007. Selective suppression of dendritic cell functions by *Mycobacterium ulcerans* toxin mycolactone. J Exp Med 204:1395-403.

43. Meier JL, Burkart MD. 2011. Proteomic analysis of polyketide and nonribosomal peptide biosynthesis. *Curr Opin Chem Biol* 15:48-56.
44. Boulkroun S, Guenin-Mace L, Thoulouze MI, Monot M, Merckx A, Langsley G, Bismuth G, Di Bartolo V, Demangel C. 2010. Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. *J Immunol* 184:1436-44.
45. Pahlevan AA, Wright DJ, Andrews C, George KM, Small PL, Foxwell BM. 1999. The inhibitory action of *Mycobacterium ulcerans* soluble factor on monocyte/T cell cytokine production and NF-kappa B function. *J Immunol* 163:3928-35.
46. Torrado E, Fraga AG, Logarinho E, Martins TG, Carmona JA, Gama JB, Carvalho MA, Proença F, Castro AG, Pedrosa J. 2010. IFN- γ -Dependent Activation of Macrophages during Experimental Infections by *Mycobacterium ulcerans* Is Impaired by the Toxin Mycolactone. *The Journal of Immunology* 184:947.
47. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, Brosch R, Jenkin GA, Johnson PD, Davies JK, Lee RE, Adusumilli S, Garnier T, Haydock SF, Leadlay PF, Cole ST. 2004. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of *Mycobacterium ulcerans*. *Proc Natl Acad Sci U S A* 101:1345-9.
48. Stinear TP, Pryor MJ, Porter JL, Cole ST. 2005. Functional analysis and annotation of the virulence plasmid pMUM001 from *Mycobacterium ulcerans*. *Microbiology* 151:683-92.
49. Roupie V, Pidot SJ, Einarsdottir T, Van Den Poel C, Jurion F, Stinear TP, Huygen K. 2014. Analysis of the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase domains in *Mycobacterium ulcerans* infected mice. *PLoS Negl Trop Dis* 8:e2604.
50. Chua BY, Zeng W, Jackson DC. 2008. Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines. *Methods Mol Biol* 494:247-61.
51. Wang Z, Kedzierski L, Nuessing S, Chua BY, Quinones-Parra SM, Huber VC, Jackson DC, Thomas PG, Kedzierska K. 2016. Establishment of memory CD8+ T cells with live attenuated influenza virus across different vaccination doses. *J Gen Virol* 97:3205-3214.
52. Coutanceau E, Legras P, Marsollier L, Reyssset G, Cole ST, Demangel C. 2006. Immunogenicity of *Mycobacterium ulcerans* Hsp65 and protective efficacy of a *Mycobacterium leprae* Hsp65-based DNA vaccine against Buruli ulcer. *Microbes Infect* 8:2075-81.
53. Trigo G, Martins TG, Fraga AG, Longatto-Filho A, Castro AG, Azeredo J, Pedrosa J. 2013. Phage therapy is effective against infection by *Mycobacterium ulcerans* in a murine footpad model. *PLoS Negl Trop Dis* 7:e2183.
54. Watanabe M, Nakamura H, Nabekura R, Shinoda N, Suzuki E, Saito H. 2015. Protective effect of a dewaxed whole-cell vaccine against *Mycobacterium ulcerans* infection in mice. *Vaccine* 33:2232-9.
55. Dangy JP, Scherr N, Gersbach P, Hug MN, Bieri R, Bomio C, Li J, Huber S, Altmann KH, Pluschke G. 2016. Antibody-Mediated Neutralization of the Exotoxin Mycolactone, the Main Virulence Factor Produced by *Mycobacterium ulcerans*. *PLoS Negl Trop Dis* 10:e0004808.
56. Porter JL, Tobias NJ, Pidot SJ, Falgner S, Tuck KL, Vettiger A, Hong H, Leadlay PF, Stinear TP. 2013. The cell wall-associated mycolactone polyketide synthases are necessary but not sufficient for mycolactone biosynthesis. *PLoS One* 8:e70520.
57. Pidot SJ, Porter JL, Marsollier L, Chauty A, Migot-Nabias F, Badaut C, Benard A, Ruf MT, Seemann T, Johnson PD, Davies JK, Jenkin GA, Pluschke G, Stinear TP. 2010. Serological evaluation of *Mycobacterium ulcerans* antigens identified by comparative genomics. *PLoS Negl Trop Dis* 4:e872.

- 810 58. Pidot SJ, Hong H, Seemann T, Porter JL, Yip MJ, Men A, Johnson M, Wilson P, Davies JK,
811 Leadlay PF, Stinear TP. 2008. Deciphering the genetic basis for polyketide variation among
812 mycobacteria producing mycolactones. BMC Genomics 9:462.
- 813 59. Meyers Wm Fau - Shelly WM, Shelly Wm Fau - Connor DH, Connor Dh Fau - Meyers EK,
814 Meyers EK. Human Mycobacterium ulcerans infections developing at sites of trauma to
815 skin.
- 816 60. Omansen TF, Porter JL, Johnson PDR, van der Werf TS, Stienstra Y, Stinear TP. 2015. In-vitro
817 Activity of Avermectins against Mycobacterium ulcerans. PLoS Neglected Tropical Diseases
818 9:e0003549.
- 819 61. Omansen TF, Marcsisin RA, Chua BY, Zeng W, Jackson DC, Porter JL, Stienstra Y, van der
820 Werf TS, Stinear TP. 2019. In Vivo Imaging of Bioluminescent Mycobacterium ulcerans: A
821 Tool to Refine the Murine Buruli Ulcer Tail Model. Am J Trop Med Hyg In Press.
- 822 62. Van Belle V, Pelckmans K, Van Huffel S, Suykens JA. 2011. Support vector methods for
823 survival analysis: a comparison between ranking and regression approaches. Artif Intell
824 Med 53:107-18.
- 825 63. Marion E, Jarry U, Cano C, Savary C, Beauvillain C, Robbe-Saule M, Preisser L, Altare F,
826 Delneste Y, Jeannin P, Marsollier L. 2016. FVB/N Mice Spontaneously Heal Ulcerative
827 Lesions Induced by Mycobacterium ulcerans and Switch M. ulcerans into a Low
828 Mycolactone Producer. Journal of Immunology 196:2690-2698.
- 829 64. Bénard A, Sala C, Pluschke G. 2016. Mycobacterium ulcerans Mouse Model Refinement for
830 Pre-Clinical Profiling of Vaccine Candidates. PLOS ONE 11:e0167059.
- 831 65. Kamala T. Hock immunization: a humane alternative to mouse footpad injections.
- 832 66. O'Brien DP, Murrie A, Meggyesy P, Priestley J, Rajcoomar A, Athan E. 2019. Spontaneous
833 healing of Mycobacterium ulcerans disease in Australian patients. PLoS Negl Trop Dis
834 13:e0007178.
- 835 67. Marion E, Chauty A, Kempf M, Le Corre Y, Delneste Y, Croue A, Marsollier L. 2016. Clinical
836 Features of Spontaneous Partial Healing During Mycobacterium ulcerans Infection. Open
837 Forum Infect Dis 3:ofw013.
- 838 68. Silva-Gomes R, Marcq E, Trigo G, Gonçalves CM, Longatto-Filho A, Castro AG, Pedrosa J,
839 Fraga AG. 2015. Spontaneous Healing of Mycobacterium ulcerans Lesions in the Guinea Pig
840 Model. PLOS Neglected Tropical Diseases 9:e0004265.
- 841 69. Tan AC, Mifsud Ej Fau - Zeng W, Zeng W Fau - Edenborough K, Edenborough K Fau -
842 McVernon J, McVernon J Fau - Brown LE, Brown Le Fau - Jackson DC, Jackson DC. Intranasal
843 administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in
844 mice.
- 845 70. Mifsud EJ, Tan AC, Reading PC, Jackson DC. Mapping the pulmonary environment of
846 animals protected from virulent H1N1 influenza infection using the TLR-2 agonist
847 Pam(2)Cys.
- 848 71. Mifsud EJ, Tan AC, Short KR, Brown LE, Chua BY, Jackson DC. Reducing the impact of
849 influenza-associated secondary pneumococcal infections.
- 850 72. Gooding TM, Johnson PD, Campbell DE, Hayman JA, Hartland EL, Kemp AS, Robins-Browne
851 RM. 2001. Immune response to infection with *Mycobacterium ulcerans*. Infect Immun
852 69:1704-7.
- 853 73. Tolosie K, Sharma MK. Application of cox proportional hazards model in case of
854 tuberculosis patients in selected addis ababa health centres, ethiopia.
- 855 74. Cole Sr Fau - Hudgens MG, Hudgens MG. Survival analysis in infectious disease research:
856 describing events in time.
- 857 75. Forster AJ, Taljaard M, Oake N, Wilson K, Roth V, van Walraven C. 2012. The effect of
858 hospital-acquired infection with Clostridium difficile on length of stay in hospital. CMAJ :

- Canadian Medical Association journal = journal de l'Association medicale canadienne
184:37-42.
76. Kalia V, Sarkar S. 2018. Regulation of Effector and Memory CD8 T Cell Differentiation by IL-2-A Balancing Act. *Front Immunol* 9:2987.
77. Fraga AG, Cruz A Fau - Martins TG, Martins Tg Fau - Torrado E, Torrado E Fau - Saraiva M, Saraiva M Fau - Pereira DR, Pereira Dr Fau - Meyers WM, Meyers Wm Fau - Portaels F, Portaels F Fau - Silva MT, Silva Mt Fau - Castro AG, Castro Ag Fau - Pedrosa J, Pedrosa J. *Mycobacterium ulcerans* triggers T-cell immunity followed by local and regional but not systemic immunosuppression.
78. Phillips R, Sarfo FS, Guenin-Mace L, Decalf J, Wansbrough-Jones M, Albert ML, Demangel C. 2009. Immunosuppressive signature of cutaneous *Mycobacterium ulcerans* infection in the peripheral blood of patients with buruli ulcer disease. *J Infect Dis* 200:1675-84.
79. Kiszewski AE, Becerril E, Aguilar LD, Kader IT, Myers W, Portaels F, Hernandez Pando R. 2006. The local immune response in ulcerative lesions of Buruli disease. *Clin Exp Immunol* 143:445-51.
80. Peduzzi E, Groeper C Fau - Schutte D, Schutte D Fau - Zajac P, Zajac P Fau - Rondini S, Rondini S Fau - Mensah-Quainoo E, Mensah-Quainoo E Fau - Spagnoli GC, Spagnoli Gc Fau - Pluschke G, Pluschke G Fau - Daubenberger CA, Daubenberger CA. Local activation of the innate immune system in Buruli ulcer lesions.
81. Ray JCJ, Wang J, Chan J, Kirschner DE. 2008. The timing of TNF and IFN-gamma signaling affects macrophage activation strategies during *Mycobacterium tuberculosis* infection. *Journal of theoretical biology* 252:24-38.
82. Cavalcanti YV, Brelaz MC, Neves JK, Ferraz JC, Pereira VR. 2012. Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis. *Pulm Med* 2012:745483.
83. Hall BS, Hill K, McKenna M, Ogbechi J, High S, Willis AE, Simmonds RE. 2014. The Pathogenic Mechanism of the *Mycobacterium ulcerans* Virulence Factor, Mycolactone, Depends on Blockade of Protein Translocation into the ER. *PLOS Pathogens* 10:e1004061.
84. Pahlevan AA, Wright DJM, Andrews C, George KM, Small PLC, Foxwell BM. 1999. The Inhibitory Action of Mycobacterium ulcerans Soluble Factor on Monocyte/T Cell Cytokine Production and NF-κB Function. *J Immunol* 163:3928.
85. Torrado E, Adusumilli S, Fraga AG, Small PLC, Castro AG, Pedrosa J. 2007. Mycolactone-Mediated Inhibition of Tumor Necrosis Factor Production by Macrophages Infected with *Mycobacterium ulcerans* Has Implications for the Control of Infection. *Infect Immun* 75:3979.
86. Bieri R, Bolz M, Ruf M-T, Pluschke G. 2016. Interferon-γ Is a Crucial Activator of Early Host Immune Defense against *Mycobacterium ulcerans* Infection in Mice. *PLOS Negl Trop Dis* 10:e0004450.
87. Phillips R, Horsfield C, Mangan J, Laing K, Etuaful S, Awuah P, Nyarko K, Osei-Sarpong F, Butcher P, Lucas S, Wansbrough-Jones M. 2006. Cytokine mRNA expression in *Mycobacterium ulcerans*-infected human skin and correlation with local inflammatory response. *Infect Immun* 74:2917-24.
88. Westenbrink BD, Stienstra Y, Huitema MG, Thompson WA, Klutse EO, Ampadu EO, Boezen HM, Limburg PC, van der Werf TS. 2005. Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana. *Clin Diagn Lab Immunol* 12:125-9.
89. Torrado E, Fraga AG, Logarinho E, Martins TG, Carmona JA, Gama JB, Carvalho MA, Proenca F, Castro AG, Pedrosa J. 2010. IFN-gamma-dependent activation of macrophages during experimental infections by *Mycobacterium ulcerans* is impaired by the toxin mycolactone. *J Immunol* 184:947-55.

- 908 90. Flynn JL, Chan J. 2001. Immunology of tuberculosis. *Annu Rev Immunol* 19:93-129.
- 909 91. Magcwebaba T, Dorhoi A, du Plessis N. 2019. The Emerging Role of Myeloid-Derived
910 Suppressor Cells in Tuberculosis. *Front Immunol* 10:917.
- 911 92. Boer MC, Joosten SA, Ottenhoff TH. 2015. Regulatory T-Cells at the Interface between
912 Human Host and Pathogens in Infectious Diseases and Vaccination. *Front Immunol* 6:217.
- 913 93. Isailovic N, Daigo K, Mantovani A, Selmi C. 2015. Interleukin-17 and innate immunity in
914 infections and chronic inflammation. *J Autoimmun* 60:1-11.
- 915 94. Greifenberg V, Ribechini E, Rossner S, Lutz MB. 2009. Myeloid-derived suppressor cell
916 activation by combined LPS and IFN-gamma treatment impairs DC development. *Eur J*
917 *Immunol* 39:2865-76.
- 918 95. Jiang M, Chen J, Zhang W, Zhang R, Ye Y, Liu P, Yu W, Wei F, Ren X, Yu J. 2017. Interleukin-6
919 Trans-Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells
920 via Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer. *Front Immunol*
921 8:1840.
- 922 96. Miossec P, Kolls JK. 2012. Targeting IL-17 and TH17 cells in chronic inflammation. *Nat Rev*
923 *Drug Discov* 11:763-76.
- 924 97. Forbes BR, Wannan JS, Kirkland WB. 1954. Indolent cutaneous ulceration due to infection
925 with *Mycobacterium ulcerans*. *Med J Aust* 41:475-9.
- 926 98. Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, Small PL. 2005.
927 *Mycobacterium ulcerans* toxic macrolide, mycolactone modulates the host immune
928 response and cellular location of M. ulcerans in vitro and in vivo. *Cell Microbiol* 7:1295-304.
- 929 99. Ogbechi J, Ruf MT, Hall BS, Bodman-Smith K, Vogel M, Wu HL, Stainer A, Esmon CT,
930 Ahnstrom J, Pluschke G, Simmonds RE. 2015. Mycolactone-Dependent Depletion of
931 Endothelial Cell Thrombomodulin Is Strongly Associated with Fibrin Deposition in Buruli
932 Ulcer Lesions. *PLoS Pathog* 11:e1005011.
- 933 100. George KM, Pascopella L, Welty DM, Small PL. 2000. A *Mycobacterium ulcerans* toxin,
934 mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. *Infect Immun*
935 68:877-83.
- 936 101. Hong H, Gates PJ, Staunton J, Stinear T, Cole ST, Leadlay PF, Spencer JB. 2003. Identification
937 using LC-MSn of co-metabolites in the biosynthesis of the polyketide toxin mycolactone by
938 a clinical isolate of *Mycobacterium ulcerans*. *Chem Commun (Camb)*:2822-3.
- 939 102. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of
940 bacteriophage T4. *Nature* 227:680-5.
- 941 103. Sekiya T, Yamagishi J, Gray JHV, Whitney PG, Martinelli A, Zeng W, Wong CY, Sugimoto C,
942 Jackson DC, Chua BY. 2017. PEGylation of a TLR2-agonist-based vaccine delivery system
943 improves antigen trafficking and the magnitude of ensuing antibody and CD8(+) T cell
944 responses. *Biomaterials* 137:61-72.
- 945 104. Wijayadikusumah AR, Zeng W, McQuilten HA, Wong CY, Jackson DC, Chua BY. 2019.
946 Geometry of a TLR2-Agonist-Based Adjuvant Can Affect the Resulting Antigen-Specific
947 Immune Response. *Mol Pharm* 16:2037-2047.
- 948 105. Chua BY, Pejowski D, Turner SJ, Zeng W, Jackson DC. 2011. Soluble proteins induce strong
949 CD8+ T cell and antibody responses through electrostatic association with simple cationic
950 or anionic lipopeptides that target TLR2. *J Immunol* 187:1692-701.
- 951 106. Beasley TM, Erickson S, Allison DB. 2009. Rank-based inverse normal transformations are
952 increasingly used, but are they merited? *Behav Genet* 39:580-95.
- 953 107. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, Blondel M,
954 Prettenhofer P, Weiss R, Dubourg V, Vanderplas J, Passos A, Cournapeau D, Brucher M,
955 Perrot M, Duchesnay E. 2011. Scikit-learn: Machine Learning in Python. *J Mach Learn Res*
956 12:2825-2830.

957 108. Polsterl S, Gupta P, Wang L, Conjeti S, Katouzian A, Navab N. 2016. Heterogeneous
958 ensembles for predicting survival of metastatic, castrate-resistant prostate cancer patients.
959 F1000Res 5:2676.

960 109. Evers L, Messow CM. 2008. Sparse kernel methods for high-dimensional survival data.
961 Bioinformatics 24:1632-8.

962 110. Shivaswamy PK, Chu W, Jansche M. 2007. A support vector approach to censored targets.
963 Icdm 2007: Proceedings of the Seventh Ieee International Conference on Data Mining
964 doi:10.1109/Icdm.2007.93:655-+.

965 111. van der Maaten L, Hinton G. 2008. Visualizing Data using t-SNE. J Mach Learn Res 9:2579-
966 2605.

967 112. Team RC. 2014. R: A Language and Environment for Statistical Computing, R Foundation for
968 Statistical Computing, Vienna, Austria. <http://www.R-project.org/>.

969 113. Bolz M, Kerber S, Zimmer G, Pluschke G. 2015. Use of Recombinant Virus Replicon Particles
970 for Vaccination against Mycobacterium ulcerans Disease. PLoS Negl Trop Dis 9:e0004011.

971 114. Fenner F. 1957. Homologous and heterologous immunity in infections of mice with
972 *Mycobacterium ulcerans* and *Mycobacterium balnei*. Am Rev Tuberc 76:76-89.
973

974

975 **Table 1. Summary of putative *M. ulcerans* vaccines tested in murine model of BU infection.**

Vaccine type	Description of components	<i>M. ulcerans</i> challenge dose	Test for mycolactone production ^a	Challenge model	Efficacy compared to BCG	Ref
DNA-based	pCDNA3 vector encoding Hsp65	10 ⁴ AFB (strain 1615 ATCC35840)	Not mentioned	Tail	Less protective	(52)
DNA-based	V1Jns.tPA vector encoding Ag85A	3 x 10 ⁴ AFB (strain 5150) or 10 ⁵ AFB (strain 04-855)	Not mentioned	Footpad	Less protective	(32, 33)
DNA-based	Primary vaccination with V1Jns.tPA plasmid encoding mycolactone polyketide domains and boosted with recombinant domain proteins emulsified in Gerbu adjuvant.	10 ⁵ AFB (strain 1615)	Not mentioned	Footpad	Less protective	(49)
Viral	Vesicular stomatitis virus (VSV) replicon particles expressing <i>M. ulcerans</i> codon optimised antigens MUL_2232 and MUL_3720	30µl of 2.8 x 10 ⁵ CFU/ml stock (8.4 x 10 ³ CFU/dose) (strain S1013)	Not mentioned	Footpad	Less protective	(113)
Subunit	MUL2232 and MUL3720 adjuvanted with GLA-SE (EM408)	1.5 x 10 ⁶ or 1.5 x 10 ⁵ CFU (strain S1013)	Not mentioned	Footpad	Less protective	(34)
Live Cell	<i>M. ulcerans</i>	10 ^{6.3} or 10 ^{4.3} viable bacteria	Not mentioned	Footpad	Less protective	(114)
Live cell	<i>M. marinum</i>	10 ⁵ bacteria (strain 1615)	Not mentioned	Footpad	More protective ^b	(35)
Live cell recombinant	<i>M. marinum</i> expressing Ag85A (on vector)	10 ⁵ bacteria (strain 1615)	Not mentioned	Footpad	More protective ^b	(35)
Live cell recombinant	<i>M. bovis</i> BCG expressing Ag85A (on vector pMV261)	10 ⁵ bacteria (strain 1615)	Not mentioned	Footpad	More protective	(36)
Live cell recombinant	<i>M. bovis</i> BCG expressing Ag85B-EsxH fusion protein Ag85A (on vector pMV261)	10 ⁵ bacteria (strain 1615)	Not mentioned	Footpad	More protective	(37)

Inactivated whole cell	Mycolactone-negative <i>M. ulcerans</i> (strain 5114)	4 log ₁₀ or 3 log ₁₀ CFU (strain 98-912)	Not mentioned	Footpad	Less protective	(25)
Inactivated whole cell	Mycolactone-deficient attenuated <i>M. ulcerans</i> (strain ATCC19423)	10 ⁶ bacteria (strain TMC1615)	Not mentioned	Footpad	Not compared	(54)
Inactivated whole cell	Formalin-treated <i>M. ulcerans</i> (strain TMC1615)	10 ⁶ bacteria (strain TMC1615)	Not mentioned	Footpad	Not compared	(54)
Inactivated whole cell	Dewaxed <i>M. ulcerans</i> (strain TMC1615)	10 ⁶ bacteria (strain TMC1615)	Not mentioned	Footpad	Not compared	(54)
Phage	Mycobacteriophage D29 (therapeutic vaccine)	5.5 log ₁₀ AFB (strain 1615)	Not mentioned	Footpad	Not comparable	(53)

^a Identifying whether the bacterial culture used for challenge was assessed for mycolactone production before infection.

^b Vaccine was more protective than the BCG vaccine, however all mice eventually developed footpad swelling.

Table 2: High-scoring immune features associated with delayed bioluminescence

Feature number	Feature	Tissue site	Association with delayed bioluminescence	Concordance index
1.	IFN-γ	spleen	negative	0.786
2.	IL-2	spleen	positive	0.769
3.	IL-6	spleen	negative	0.759
4.	TNF-α	spleen	negative	0.745
5.	IL-2	lymph node	positive	0.715
6.	IFN-γ CD4 ⁺ T-cell	spleen	negative	0.707

Figures: Figure 1

Figure 1. Analysis of purified recombinant ER protein antigen characteristics and formulation with R₄Pam₂Cys. (A) The presence of recombinant ER protein (~37 kDa) was monitored by SDS-PAGE at each stage of the purification process; Lane: 1 - Whole cell lysate (WCL), Lane 2 - Wash 1, Lane 3 - Wash 7 and Lane 4 – ER protein elution (containing 10 μ g protein). **(B)** Western Blot using an anti-

990 6xHIS-tag antibody to detect the presence of a single band corresponding to the correct molecular
 991 weight of the ER protein in the final eluate. **(C)** To analyse the formation of antigen-lipopeptide
 992 complexes, a constant amount of antigen was mixed with lipopeptide at different
 993 protein:lipopeptide molecular ratios in 50µl of PBS. The size distribution of particles was then
 994 analysed by DLS with each profile depicting the hydrodynamic radius (nm) of complexes in each
 995 solution. The average radius of each formulation is highlighted in the accompanying table. **(D)**
 996 BALB/c mice (n=5/group) were vaccinated on day 0 and day 21 with R₄Pam₂Cys alone, ER antigen
 997 alone or antigen formulated with R₄Pam₂Cys or vaccinated with BCG on day 0 only. Total serum
 998 (IgG) antibody against recombinant ER protein were measured by ELISA after the primary dose (day
 999 20) and two weeks after the secondary dose (day 35). Statistical tests were conducted at the 5%
 1000 significance level. The null hypothesis was rejected if there was a significant difference in mean
 1001 antibody responses between treatment groups. Note: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ or **** p
 1002 < 0.0001 . The error bars represent standard deviation (n=5).

1003

1004

1005

Figure. 2

Figure 2. Characterisation of infection using a low-dose bioluminescent *M. ulcerans* strain.

Representative light camera images of tails from (A) an uninfected BALB/c mouse or (B) at the point of ulceration (16 weeks) following intradermal inoculation with 20 CFU of bioluminescent *M. ulcerans*. (C, D) The same tails were visualised under an IVIS camera to detect and quantify bioluminescence intensity (as photons/sec). Histological cross section of an (E, F) uninfected or (G, H) infected tail tissue following haematoxylin & eosin (H&E) and Ziehl-Neelson (ZN) staining. Zoomed images of the regions indicated within the denoted boxes of (H) and depicts the presence of polymorphonuclear cells (PMNs) and acid-fast bacilli (ZN staining) within tissue (I, J).

1017 Figure. 3

1018

1019 **Figure 3. Development of BU over time after vaccination.** (A) Tails of mice were intradermally
1020 infected with 20 CFU of bioluminescent *M. ulcerans* and imaged weekly by IVIS. Representative

panels depict the weekly progression of bioluminescent *M. ulcerans* burden in the tail of an unvaccinated mouse over the course of 16 weeks expressed as photons/second. BALB/c mice (n=10/group) were left **(B)** unvaccinated, or vaccinated on day 0 and day 21 with **(C)** ER antigen alone, **(D)** R4Pam₂Cys alone, , **(E)** ER antigen formulated with R4Pam₂Cys or **(F)** on day 0 with BCG followed by challenge on week 5 with bioluminescent *M. ulcerans*. Threshold bioluminescence (threshold lux) for disease was defined as $\geq 5 \times 10^5$ photons/second (p/s) as mice that reached this level typically progressed to the clinical (ethical) end point. Mice were classified as diseased if they reached this end point within the 24-weeks following challenge or if their bioluminescence value at week 24 was $\geq 5 \times 10^5$ p/s. Mice were classified as protected if they did not reach this clinical end point and their bioluminescence value was $< 5 \times 10^5$ photons/second. The data point depicting when an infected mouse first exhibited bioluminescence at $\geq 5 \times 10^5$ p/s is represented with a yellow symbol. The data point denoting when a mouse reached clinical endpoint is represented with a blue symbol. Protected mice with detectable bioluminescence are depicted as grey symbols. **G.** Time to bioluminescence measured by IVIS. A survival curve was utilised to analyse the time (weeks) taken for each BU diseased mouse to first reach threshold bioluminescence $\geq 5 \times 10^5$ photons/second. BCG group (upside down triangle) is labelled in blue, ER + R4Pam₂Cys (circle) is red, and ER alone (square), R4Pam₂Cys alone (upright triangle) and no vaccine (diamond) groups are depicted in grey. Statistical tests were conducted at the 5% significance level. The null hypothesis was rejected if there was a significant difference in survival between groups. Note: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ or **** $p < 0.0001$.

1042 Figure 4

1043

1044 **Figure 4. Immune responses after *M. ulcerans* infection.** BALB/c mice (n=10/group) were left
1045 unvaccinated or vaccinated on day 0 and day 21 with ER antigen alone, ER antigen formulated with
1046 R₄Pam₂Cys, R₄Pam₂Cys alone, or on day 0 with BCG followed by challenge on day 36 with
1047 bioluminescent *M. ulcerans*. **(A)** Total serum (IgG) antibody against recombinant ER protein were
1048 measured by ELISA after the experimental end point. All data points for diseased mice

(bioluminescence $\geq 5 \times 10^5$ p/s) are depicted with white symbols. Statistical tests were conducted at the 5% significance level. The null hypothesis was rejected if there was a significant difference in mean antibody responses between treatment groups. The error bars represent standard deviation.

(B) After experimental end point was reached, CD4⁺ IFN- γ ⁺ T cells were enumerated from the spleen of mice in response to ER protein. The null hypothesis was rejected if there was a significant difference in mean CD4⁺ IFN- γ ⁺ T cells between treatment groups. Once experimental end point was reached, cytokines from draining lymph nodes and spleens of *M. ulcerans* challenged mice were also measured in response to *in vitro* cell stimulation with recombinant ER protein (Supplementary Table S1). Shown here are cytokine titres **(C)** IFN- γ produced from immune cells in the draining lymph nodes and **(D)** TNF produced from immune cells in the spleen. The null hypothesis was rejected if there was no difference in mean cytokine titres between treatment groups. The black bars represent the mean. Fold change of mean cytokine titres from protected mice (bioluminescence $< 5 \times 10^5$ p/s) and diseased mice (bioluminescence $\geq 5 \times 10^5$ p/s) over naïve mice were compared in the **(E)** spleen and **(F)** draining lymph nodes. The null hypothesis was rejected if there was a significant difference in mean cytokine titres between treatment groups. All statistical tests were conducted at the 5% significance level. Note: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ or **** $p < 0.0001$.

1067 Figure 5

1068

1069

1070

1071

1072

Figure 5. Statistical modelling to identify immune parameters (features) associated with vaccine protection. Univariate Cox Proportional hazards models were specified for each of the 28 immunological features to test their association with the response variable (time-to-bioluminescence measured in weeks). The resulting concordance index (CI) scores were obtained

and the six features with a CI >0.7 were retained. The inverse associations of the top two features
(A) IFN- γ and **(B)** IL-2 produced in murine splenocytes at the experimental end-point. **(C)** Plot
depicting a two-dimensional representation of the top six features that associate with time-to-
bioluminescence from the unsupervised t-SNE. The shapes/colours indicate the two groups
identified through K-means clustering, of bioluminescence by 8-17 weeks or at 18 weeks and
beyond (up to 24 weeks). **(D)** Receiver operator curve (and corresponding area under curve),
displaying the trade-off between sensitivity and specificity across all thresholds for 1,000 random
train-test splits of a logistic regression classifier (90% of observations used for training). The red
dotted line depicts the expectation of a random classifier and the blue line depicts the model
performance. **(E)** Proportion of observations across treatment groups for each of the classes both
8-17 weeks and 18-24 weeks and those with no detection. **(F)** Group-specific univariate logistic
regression analyses for each of the five treatment groups. Model coefficients were used to
determine both the strength and direction of association of each feature with that of each
treatment group. Depicted are those features with a corresponding p-value<0.05 (Table S2).

1090 **Supplementary data**

1091 **Table S1** - Vaccination data

1092 **Table S2** - Summary of group-specific univariate logistic regression coefficients

1093